Piper Sandler Upgrades NovoCure to Overweight, Announces $45 Price Target
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Jason Bednar has upgraded NovoCure (NASDAQ:NVCR) from Neutral to Overweight and announced a $45 price target.
August 08, 2023 | 9:09 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NovoCure has been upgraded from Neutral to Overweight by Piper Sandler, with a new price target of $45.
The upgrade from Neutral to Overweight by Piper Sandler indicates a positive outlook for NovoCure. The new price target of $45 also suggests potential upside for the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100